Pivot Park and Aspen Oss, both located in Oss and neighbours of each other, have signed an important letter of intent for the development and lease of the Hodgkin building, commonly known as “Panther”, at Pivot Park by Aspen Oss. Together, they will further explore how the interior should be laid out and whether they can reach agreement on this. The planned collaboration underlines the strengthening of the pharmaceutical cluster in Oss.
This step will enable Aspen Oss and its sister company BioChem Oss to cluster all laboratory activities currently carried out in various buildings at the Moleneind site in Oss. “The new, state-of-the-art building on the Pivot Park site offers modern facilities for both laboratory and office functions, and thus fits in seamlessly with the ambitions of Aspen Oss and BioChem Oss. The building complies with all industrial hygiene and safety regulations as well as GMP requirements, and has been designed with future-proofing and sustainability in mind, meeting the highest standards of energy efficiency. This also strengthens our attractiveness as a partner to customers and to new and existing talent,” says Marcel Broecks (Site Director Aspen Oss).
Expansion of ecosystem
Pivot Park is delighted with the intention to work more closely with Aspen Oss. “Due to circumstances, Panther has been waiting for some time to be put into use. We are therefore particularly pleased to have signed the letter of intent together with this partner within the Oss pharma cluster. This will enable us to start designing and setting up the facility. In doing so, we are strengthening the ecosystem that is so important for a campus like Pivot Park,” said Brigitte Drees (CEO Pivot Park).
The exploration of Panther’s layout will run until the end of August 2025, with the aim of having the first employees move into the building in June 2027. The first appointments to set this process in motion have already been scheduled.



